

**CANCER REPORTING IN CALIFORNIA:**  
**ABSTRACTING AND CODING PROCEDURES**  
**California Cancer Reporting System Standards, Volume I**

*Changes and Clarifications–23<sup>rd</sup> Edition*  
*September 2023*

**Quick Look - Updates to Volume I**

**New Data Items**

<b><u>VOL I Section #</u></b>	<b><u>Data Item</u></b>	<b><u>Requirement</u></b>
Appendix Q	Histologic Subtype	Required
Appendix Q	Clinical Margin Width	Required
III.2.15	No Patient Contact Flag	Required
VI.2.4-V.12.11; Appendix K.2	RX Hosp--Surg Prim Site 2023	Required
VI.2.4-V.12.11; Appendix K.2	RX Summ--Surg Prim Site 2023	Required

**Section/Page Revisions**

<b><u>VOL I Section #</u></b>	<b><u>Data Item or Volume I Topic</u></b>	<b><u>Reason for Revision</u></b>
I.1.2	The California Cancer Registry	Updated SEER coverage area statistic
I.1.6	Reporting	Updated reporting requirements; table name
I.1.6.3	Entering Dates	Removed Date Flag column in table
I.1.6.4	Date Format	Renamed Page; Updated coding instructions; removed Date Flag column in table
II.1	CCR Reportability Guide - Reportable	Updated coding instructions; Errata 2022; terms indicating in-situ behavior; formatting of Standard Setter Differences; separated non-site specific reportability from site-specific reportability; added 2023 reportability requirements; removed thyroid reportability and moved to II.1.1
II.1.1	CCR Reportability Guide - Non-Reportable or Historically Reportable	Added thyroid and requirement end date; Errata 2022
II.2.5	Benign/Borderline Brain and CNS Tumors	Added formatting for Standard Setter Difference
II.3.3	Sequence Number	Updated coding instructions
III.2.10	Race and Ethnicity	Updated race code descriptions
III.2.10.1	Codes for Race Data Item	Updated race code descriptions in table
III.2.11	Date of Birth	Removed references to Date Flag/Date Flag Guide
III.2.15	No Patient Contact Flag	Renamed Page; reallocated to No Patient Contact Flag from Patient-No Research Contact flag; updated coding instructions to align with new NAACCR data item
III.2.18.2	Tobacco Use Smoking Status	Updated code 1 description in table
III.3.1	Date of First Contact	Removed references to Date Flag/Date Flag Guide
III.3.2	Dates of Inpatient Admission and Inpatient Discharge	Removed references to Date Flag/Date Flag Guide
III.3.3	Date of Diagnosis	Removed references to Date Flag/Date Flag Guide

III.3.5	Class of Case	Updated definition for nonanalytic cases; revised class descriptions for codes 30, 34, and 36
III.3.9	Payment Source (Primary and Secondary) and Payment Source Text	Updated coding instructions for codes 28-29; revised descriptions for codes 31 and 35 in table
IV.1	Text - Diagnostic Procedures Performed	Updated introduction, removed comment regarding text length
IV.1.1-IV.1.3	Text - Physical Examination, Text - X-Ray/Scans, Text - Scopes	Added coding instructions
IV.1.6	Text - Pathology Findings	Added/revised coding instructions
V.2.1	Laterality - Paired Sites	Added/removed sites from table; Errata 2022
V.3.3	Behavior	Moved coding instruction to reference under table
V.3.3.1	In-Situ Coding	Updated general and site-specific terms lists indicating in-situ behavior; Errata 2022
V.5.1	Tumor Size Clinical	Clarification to timing rules
V.5.2	Tumor Size Pathologic	Updated coding instructions; Errata 2022
V.7	Lymphovascular Invasion	Added coding instruction; example; updated table
V.8	Terms Indicating In-situ for Staging	Updated coding instructions; Errata 2022
V.9.1	Staging Requirements	Updated Guideline; updated staging requirements
V.10	AJCC TNM Staging	Updated introduction
V.10.2	AJCC TNM Edition Number	Updated coding instruction; updated table
VI.1.3.1-VI.1.3.3	Neoadjuvant Therapy, Neoadjuvant Therapy - Clinical Response, Neoadjuvant Therapy - Treatment Effect	Added coding instructions
VI.2	Surgery Introduction - First Course of Treatment	Added coding instruction
VI.2.3	Diagnostic or Staging Procedures	Updated coding instruction priority order
VI.2.3.1	Date of Diagnostic or Staging Surgical Procedures	Removed references to Date Flag/Date Flag Guide
VI.2.4	Surgery of Primary Site 2023	Renamed page; updated page to new four-character alphanumeric surgery codes
VI.4.2.1	Date of Surgery	Removed references to Date Flag/Date Flag Guide
VI.2.5.1	Date of Sentinel Lymph Node Biopsy	Removed references to Date Flag/Date Flag Guide
VI.2.6.1	Date of Regional Lymph Node Dissection	Removed references to Date Flag/Date Flag Guide
VI.3	Radiation Therapy - First Course of Treatment	Removed references to Date Flag/Date Flag Guide; added coding instruction
VI.3.2	Date of Radiation Therapy	Removed references to Date Flag/Date Flag Guide
VI.4	Chemotherapy - First Course of Treatment	Removed references to Date Flag/Date Flag Guide; added coding instruction
VI.4.2	Date of Chemotherapy	Removed references to Date Flag/Date Flag Guide
VI.5	Hormone (Endocrine) Therapy - First Course of Treatment	Removed references to Date Flag/Date Flag Guide
VI.5.2	Date of Hormone Therapy	Removed references to Date Flag/Date Flag Guide
VI.6	Immunotherapy (Biological Response Modifier Therapy) - First Course of Treatment	Removed references to Date Flag/Date Flag Guide; added coding instruction

VI.6.2	Date of Immunotherapy	Removed references to Date Flag/Date Flag Guide
VI.7.1	Date of Transplant/Endocrine Procedure	Removed references to Date Flag/Date Flag Guide
VI.8.1	Date of Other Therapy	Removed references to Date Flag/Date Flag Guide
VI.9	RX Summary – Treatment Status	Renamed data item to Surgery of Primary Site 2023 from Surgery of Primary Site
VI.10	Protocol Participation	Updated coding instruction for text
VII.2.1	Date of Last Contact (AKA Date Last Pt FU)	Removed references to Date Flag/Date Flag Guide
VII.2.3	Date of Last Cancer (Tumor) Status	Removed references to Date Flag/Date Flag Guide
VII.2.9-VII.2.12.1	Follow-Up Physician, Date of First Recurrence, Type of First Recurrence, Place of Death - Country, Place of Death - State	Pages renumbered; removed references to Date Flag/Date Flag Guide
VIII.1	Text - Remarks	Updated coding instructions
IX.1.2	Modified Record	Updated coding instructions
Appendix G	Codes for Casefinding	Updated using SEER casefinding list v23
Appendix K.1	STORE Surgery Codes for 2010-2022	Renamed page; revised introduction; updated historical code references; renamed each site/section to K.1
Appendix K.2	STORE Surgery Codes for 2023 +	New page; four-character alphanumeric surgery codes
Appendix M	Q-Tips	Revised list of Q-Tips; updated link
Appendix Q	Site-Specific Data Items (SSDIs)	Added/removed codes/terms
Appendix R	Coding Resources	Updated resources
Appendix S	Historical Coding and Staging Manual Requirements for CCR	Added historical manuals
Appendix T	Text Documentation Guidelines	Updated text documentation guidelines; Errata 2022

### Items No Longer Required/Pages Deleted

<b>VOL I Section # (HISTORICAL NOW)</b>	<b>Data Item</b>	<b>Requirement</b>
III.2.11.1	Date of Birth Flag	Page deleted, Date Flags are retired as of 2023
III.3.1.1	Date of First Contact Flag	Page deleted, Date Flags are retired as of 2023
III.3.2.1	Date of Inpatient Admission Flag	Page deleted, Date Flags are retired as of 2023
III.3.2.2	Date of Inpatient Discharge Flag	Page deleted, Date Flags are retired as of 2023
III.3.3.1	Date of Diagnosis Flag	Page deleted, Date Flags are retired as of 2023
IV.3	COVID-19	Page deleted, discontinued for cases diagnosed in 2023
VI.2.3.1.1	Date of Diagnostic or Staging Surgical Procedures Flag	Page deleted, Date Flags are retired as of 2023
VI.2.4.1.1	Date of Surgery Flag	Page deleted, Date Flags are retired as of 2023
VI.2.5.1.1	Date of Sentinel Lymph Node Biopsy Flag	Page deleted, Date Flags are retired as of 2023
VI.2.6.1.1	Date of Regional Lymph Node Dissection Flag	Page deleted, Date Flags are retired as of 2023
VI.3.2.1	Date of Radiation Therapy Flag	Page deleted, Date Flags are retired as of 2023
VI.4.2.1	Date of Chemotherapy Flag	Page deleted, Date Flags are retired as of 2023
VI.5.2.1	Date Hormone Therapy Flag	Page deleted, Date Flags are retired as of 2023
VI.6.2.1	Date of Immunotherapy Flag	Page deleted, Date Flags are retired as of 2023

VI.7.1.1	Date of Transplant/Endocrine Procedure Flag	Page deleted, Date Flags are retired as of 2023
VI.8.1.1	Date of Other Therapy Flag	Page deleted, Date Flags are retired as of 2023
VII.2.1.1	Date of Last Contact Flag	Page deleted, Date Flags are retired as of 2023
VII.2.3.1	Date of Last Cancer (Tumor) Status Flag	Page deleted, Date Flags are retired as of 2023
VII.2.9	Next Follow-up Facility	Page deleted, item not in Volume II, Appendix B
VII.2.11.1	Date of First Recurrence Flag	Page deleted, Date Flags are retired as of 2023

## **GENERAL CHANGES**

Volume I is only presented in PDF format. For historical Volumes, see [Archived Volume I](#) - Use case year of diagnosis to determine which Volume I to choose.

### **All Pages:**

- ✓ Updated and confirmed internal and external links.
- ✓ Formatting, grammar, and editing for typos.
- ✓ Reapplied lines/border formatting to coding tables.

### **Select Pages:**

- ✓ Removed all links and references to Date Flag/Date Flag Guides throughout the volume.
- ✓ Updated any two-digit surgery codes to four-character alphanumeric throughout the volume.

## **SECTION CHANGES**

### **I.1.2 The California Cancer Registry**

- ✓ Updated the SEER statistic to 159 million people in twenty two designated area from 115 million people in seventeen designated regions.

### **I.1.6 Reporting**

- ✓ Cases Not Reportable section, Consult Only. Case description was revised to better define what is included for non-reporting of consult only cases.
- ✓ Cases Not Reportable section, under all bullets-Note removed: Essentially, Class 31, 33, 40, and 41 are not reportable to the CCR. Class 32 is to be reported through a full abstract. See Class of Case for definitions.
- ✓ Renamed table to “Required Method of Reporting by Class of Case Is Outlined in the Tables Below” from “Required Method of Reporting to the CCR.”
- ✓ Class 30, Required by CCR column – added “\*Yes (see Class of Case for exceptions) and added link to the Class of Case section.

### **I.1.6.3 Entering Dates**

- ✓ Removed Date Flag column from the table. Date Flags are now retired.
- ✓ Removed references to Date Flags. This data item is retired.
- ✓ Updated and removed column in table referencing Date Flags.

### **I.1.6.4 Date Format – *Renamed Page***

- ✓ Page renamed to Date Format; from Date Format and Date Flag Guide.
- ✓ Removed two coding instructions specific to Date Flag codes.
- ✓ Removed Date Flag related notes under table:
  - \* Allowable Date Flag values.
  - Refer to the Date Flag Guide for the allowable values for each Date Flag data item.

## **II.1 CCR Reportability Guide - Reportable**

- ✓ Updated Coding Instructions:
  - Moved note regarding when dates are not mentioned being reportable since the region’s reference date from a note within the section to the Coding Instructions at the beginning of the section.
  - Updated new histology codes reportable for 2023 and forward should not be used for cases diagnosed prior to 2023 because the histology was not reportable at the time of diagnosis.
- ✓ For Sites - Anus, Vagina, and Vulva:
  - Updated the description in Site-Specific Terms Indicating In-Situ Behavior section to “High grade squamous intraepithelial lesion rather than invasion, based on Volume I Errata-22<sup>nd</sup> Edition.
  - Added to each site: Intraepithelial neoplasia, grade II (AIN II, VAIN II, and VIN II), 8077/2, DX 01/01/2022 +, based on Volume I Errata-22<sup>nd</sup> Edition.
- ✓ Added the following note for Standard Setter Difference:
  - The CCR reportability date for AIN II, VAIN II, and VIN III is 01/01/2022 and forward. This differs from SEER’s Requirement of 01/01/2021 and forward.
- ✓ Added bolded sentence to clarify what is contained for reportability below.
  - The following are reportable diagnoses that are either new or are frequently questioned.
- ✓ Separated non-Site Specific Reportable list from the Site Specific reportable list.
  - Reportable diagnoses that are not site-specific – Added 2023+ reportable terms.
    - Lymphangi leiomyomatosis, 9173/3, dx 01/01/2023 +.
    - Mesothelioma in situ, 9050/2, dx 01/01/2023 +.
  - Site-Specific Reportability– Added 2023+ reportable terms.
    - Diffuse leptomeningeal glioneuronal tumor, C71\_, 9509/3, dx 01/01/2023 +.
    - Multinodular and vacuolating neuronal tumor 9509/0, dx 01/01/2023 +.
    - Juvenile xanthogranuloma 9749/1, 01/01/2023 + (C715 is the most common site)
    - Pilocytic astrocytoma/juvenile pilocytic astrocytoma 9421/1, for all sites, dx 01/01/2023 +.
- ✓ Updated Hemangioma, NOS to 9121/0 from 9210/0, based on Volume I Errata-22<sup>nd</sup> Edition.
- ✓ Revised standard setter difference for Juvenile astrocytoma based on 2023 updates:
  - Juvenile astrocytoma is coded as borderline in ICD-O-3; For dx 01/01/2001 to 12/31/2022 North America registries reported as 9421/3. (Per ICD-O-3 Errata dated 5/22/2001), with the exception of optic nerve (C723) which was reported as 9421/1. Starting with dx 01/01/2023 juvenile astrocytoma for all sites will be reported as 9421/1.
- ✓ Updated reportability instruction for Prostate (C619) to reference PI-RADS 4 and PI-RADS 5 rather than LR-4 & LR-5 (LR-4 & LR-5 are for liver primaries), based on Volume I Errata-22<sup>nd</sup> Edition.
- ✓ Removed the following entry from the Reportable Diagnosis list. This is being moved to II.1.1 CCR Reportability Guide - Non-Reportable or Historically Reportable. This data item was no longer reportable effective 01/01/2021, based on Volume I Errata-22<sup>nd</sup> Edition.
  - **Thyroid (C739)**
    - Non-invasive follicular thyroid neoplasm with papillary like nuclear features is a synonym for encapsulated follicular variant of papillary thyroid carcinoma, 8343/3, dx 01/01/2017 +.

### II.1.1 CCR Reportability Guide - Non-Reportable or Historically Reportable

- ✓ Added the following entry to the Non-Reportable or Historically Reportable Diagnoses list, based on Volume I Errata-22<sup>nd</sup> Edition.
- ✓ **Thyroid (C739)**

- Non-invasive follicular thyroid neoplasm with papillary like nuclear features is a synonym for encapsulated follicular variant of papillary thyroid carcinoma, 8343/2, was reportable if diagnosed between 01/01/2017-12/31/2020.
  - The behavior code was initially incorrectly added to volume I as /3 (see II.I Reportability Guide - Reportable above for Thyroid), and was updated to /2 here.
- The ICD0 3.2 histology changed to 8349/1 in the 2021 histology updates, making this diagnosis no longer reportable for cases diagnosed 01/01/2021 and forward.

### **II.2.5 Benign/Borderline Brain and CNS Tumors**

- ✓ Added formatting to have a header for the Standard Setter Differences, to promote uniformity throughout the document.

### **II.3.3 Sequence Number**

- ✓ Fourth bullet in coding instructions - Updated instruction to clarify the juvenile astrocytoma sequencing update due to behavior change in 2023.
- ✓ Fifth bullet in coding instructions - Updated reportable diagnosis date typo for primary, non-malignant tumor of brain or CNS sites to 01/01/2001 from 01/01/2007.

### **III.2.10 Race and Ethnicity**

- ✓ Updated Race descriptions throughout page:
  - To Asian, including Asian, NOS; from Asian
  - To Black or African American; from Black
  - To Unknown by patient; from Unknown
  - To Some other race; from Other
  - To Native Hawaiian; from Hawaiian

#### **III.2.10.1 Codes for Race Data Item**

- ✓ Updated code labels to reflect 2020 Census to align with national standard definitions.
  - Code 02 description modified to Black or African American; from Black.
  - Code 03 description modified to American Indian, Alaska Native (includes all indigenous populations of the Western Hemisphere); from American Indian, Alaska Native.
  - Code 07 description modified to Native Hawaiian; from Hawaiian.
  - Code 13 description modified to Cambodian; from Kampuchean Cambodian.
  - Code 15 description modified to Asian Indian, NOS or Pakistani, NOS; From Asian Indian or Pakistani, NOS.
  - Code 32 description modified to Papua New Guinean; from New Guinean.
  - Code 96 description modified to Other Asian, including Asian, NOS; from Other Asian, including Burmese, Indonesian, Asian, NOS and Oriental, NOS.
  - Code 98 description modified to Some Other Race; from Other.
  - Code 99 description modified to Unknown by patient; from Unknown.

#### **III.2.11 Date of Birth**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

##### **III.2.11.1 Date of Birth Flag – Deleted Page**

- ✓ Page deleted, all Date Flags are retired as of 2023.

### **III.2.15 No Patient Contact Flag – *Renamed Page***

- ✓ Page renamed to No Patient Contact Flag; from Patient-No Research Contact Flag. The CCR collected this data item prior to the new Standard Setter’s 2023 data item.
  - Codes changed from 6 codes to 2 codes.
  - Coding instructions updated to align with NAACCR.
  - Codes and Descriptions updated to match NAACCR.

### **III.2.18.2 Tobacco Use Smoking Status**

- ✓ Updated code 1, description to Current Smoker; from Current Someday Smoker.

### **III.3.1 Date of First Contact**

- ✓ Removed reference to Date Flag Guide. Date Flags are now retired as of 2023.

#### **III.3.1.1 Date of First Contact Flag – *Deleted Page***

- ✓ Page deleted, all Date Flags are retired as of 2023.

### **III.3.2 Dates of Inpatient Admission and Inpatient Discharge**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **III.3.2.1 Date of Inpatient Admission Flag – *Deleted Page***

- ✓ Page deleted, all Date Flags are retired as of 2023.

#### **III.3.2.2 Date of Inpatient Discharge Flag – *Deleted Page***

- ✓ Page deleted, all Date Flags are retired as of 2023.

### **III.3.3 Date of Diagnosis**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **III.3.3.1 Date of Diagnosis Flag – *Deleted Page***

- ✓ Page deleted, all Date Flags are retired as of 2023.

### **III.3.5 Class of Case**

- ✓ Revised definitions in Nonanalytic Cases section to clarify the Class of Cases that are reportable to the CCR, and how to report.
- ✓ Code 30 – Description updated to separate and clarify when Class 30 is/is not reportable to the CCR.
- ✓ Class of Case 34 and 36 – Description updated to add AIN II, VAIN II, and VIN II, reportable for cases diagnosed 01/01/2022+.

### **III.3.9 Payment Source (Primary and Secondary) and Payment Source Text**

- ✓ Updated and revised error in coding instructions for 28-29.
- ✓ Moved paragraph stating “This government administered insurance for persons who are uninsured, below the poverty level, or covered under entitlement programs. Medicaid other than described in code 35” to the definition of Class of Case 31.



## IV.1 Text - Diagnostic Procedures Performed

- ✓ Removed last sentence stating, “The length of the text data items are 1000 characters.”

### IV.1.1 Text - Physical Examination

- ✓ Added coding instructions:
  - Record the managing/treating physician’s impression/statement of the patient’s overall clinical response to neoadjuvant therapy.
  - Record required patient demographics if not recorded in Text – Remarks.

### IV.1.2 Text - X-Ray/Scans

- ✓ Updated last coding instruction to:
  - Diagnostic statement/impression of the radiologist or endoscopist, including response to neoadjuvant therapy.

### IV.1.3 Text - Scopes

- ✓ Updated second to last coding instruction to:
  - Diagnostic statement/impression of the radiologist or endoscopist, including response to neoadjuvant therapy.

### IV.1.6 Text - Pathology Findings

- ✓ Added coding instructions:
  - Treatment effect to neoadjuvant therapy as stated in the pathology report, including the treatment response score.
  - Capture any other information needed to support site-specific data items.
- ✓ Revised coding instruction to:
  - Pertinent biomarker results (recorded in SSDIs, used for staging, evaluate response to neoadjuvant therapy, etc.).

## IV.3 COVID-19 – *Deleted Page*

- ✓ Page deleted. Data collection for this data item has been discontinued for cases diagnosed 2023 and forward.

## V.2.1 Laterality – Paired Sites

- ✓ Added site code C444 to Paired Site list. This update was inadvertently omitted in the 2022 Volume I release. This is effective for cases diagnosed 01/01/2022 and forward, based on Volume I Errata-22<sup>nd</sup> Edition.
- ✓ Removed the following from the paired sites table:
  - C300 - Nasal cavity (excluding nasal cartilage, nasal septum)
  - C340 - Main bronchus (excluding carina)
  - C413 - Rib, clavicle ( excluding sternum)
  - C414 - Pelvic bones (excluding sacrum, coccyx, symphysis pubis)

## V.3.3 Behavior

- ✓ Moved the following coding instruction to become a note under the codes table as it is referenced with \*\*
  - \*\* Behavior codes of /6 or /9 per ICD-O-3 are **not** reportable. An edit error will be received when attempting to enter /6 or /9 for behavior.

### V.3.3.1 In-Situ Coding

- ✓ For Sites - Anus, Vagina, and Vulva:
  - Updated the description in Site-Specific Terms Indicating In-Situ Behavior section to “High grade squamous intraepithelial lesion rather than invasion, based on Volume I Errata-22<sup>nd</sup> Edition.
  - Added to each site: Intraepithelial neoplasia, grade II (AIN II, VAIN II, and VIN II), 8077/2, DX 01/01/2022 +, based on Volume I Errata-22<sup>nd</sup> Edition.

### V.5.1 Tumor Size Clinical

- ✓ Revised coding instruction “Timing Rules” for Tumor Size Clinical to:
  - **Timing Rules:** Tumor Size Clinical follows the timing rules for AJCC clinical staging. For clinical tumor size, take into consideration what the physician would use to assign clinical stage. Refer to AJCC TNM guidelines to determine the sources of information that pertain to the clinical staging timeframe.  
**Example:** TURBT for a bladder primary pertains to clinical staging. A size from a TURBT would be a clinical size.  
**Note:** Do **not** use the classification in the T category to infer the tumor size.

### V.5.2 Tumor Size Pathologic

- ✓ Revised coding instruction “Timing Rules” for Tumor Size Pathologic, based on Volume I Errata-22<sup>nd</sup> Edition to:
  - **Timing Rules:** Pathologic tumor size follows the timing rules for AJCC pathological staging.  
For pathologic tumor size, take into consideration what the physician would use to assign pathological stage. Refer to AJCC TNM guidelines to determine the sources of information that pertain to the pathological staging timeframe.  
**Example:** Lumpectomy and mastectomy pertain to the pathological timeframe. A size from lumpectomy or mastectomy would be used for the pathologic tumor size.  
**Notes:**
    1. Do **not** infer the tumor size from the T category.
    2. If neoadjuvant therapy has been administered, do not record the pathologic tumor size from surgery. See further instructions under code 000 and 999.
- ✓ Updated Coding Instruction for Code 000 to:
  - Code 000 when:
    - No residual tumor found in resected surgical specimen.
      - This includes when neoadjuvant therapy has been administered and the resection shows no residual tumor. For all other scenarios where neoadjuvant has been given, see code 999.

### V.7 Lymphovascular Invasion

- ✓ Code 9, added coding instruction:
  - Ambiguous terminology is used.  
**Example:** suspicious LVI
  - Added “Ambiguous terminology used” to code 9 description in table.

### V.8 Terms Indicating In-situ for Staging

- ✓ For Sites - Anus, Vagina, and Vulva:

- Updated the description in Site-Specific Terms Indicating In-Situ Behavior section to “High grade squamous intraepithelial lesion rather than invasion, based on Volume I Errata-22<sup>nd</sup> Edition.
- Added to each site: Intraepithelial neoplasia, grade II (AIN II, VAIN II, and VIN II), 8077/2, DX 01/01/2022 +, based on Volume I Errata-22<sup>nd</sup> Edition.

### **V.9.1 Staging Requirements**

- ✓ Added sub-bullet to guideline for AJCC TNM to clearly describe version 9 cancer staging system updates.
- ✓ Updated AJCC Version 9 Cancer Staging System requirements to include: Anus, Appendix, Brain & Spinal Cord, and Medulloblastoma, for cases diagnosed 2023+ in table.

### **V.10 AJCC TNM Staging**

- ✓ Revised introduction sentence to clarify that additional sites are being rolled out annually, for AJCC 9<sup>th</sup> version.

#### **V.10.2 AJCC TNM Edition Number**

- ✓ Removed sub-bullet “9<sup>th</sup> Edition (version) is to be entered for Cervix Cases only” from second bullet. This is no longer accurate.
- ✓ Removed “(currently for cervix cases only)” from code 9 description in codes table.

#### **VI.1.3.1 Neoadjuvant Therapy**

- ✓ Added coding instruction:
  - Document in the corresponding treatment text field(s) (e.g. Text-Chemotherapy, Text-Radiation Therapy):
    - If therapy is considered neoadjuvant per the treatment plan.
    - If neoadjuvant treatment is started, but not completed, as prescribed.
    - For additional information regarding recording text, please see Appendix T -Text Documentation Guidelines.

#### **VI.1.3.2 Neoadjuvant Therapy – Clinical Response**

- ✓ Added coding instruction:
  - Document information in text to support the clinical response that is coded:
    - Record in Text-Physical Examination the managing/treating physician’s interpretation/statement of response to neoadjuvant therapy, when available (codes 1-5).
    - Record in Text-Scopes and Text-Scans the radiologist or endoscopist statement /impression of the response to neoadjuvant therapy when post-neoadjuvant therapy scopes/scans are done prior to resection (code 6).
    - Record in Text-Pathology any post-neoadjuvant biopsy and/or biomarker results used to infer a clinical response (codes 6 and 7).
    - For additional information regarding recording text, please see Appendix T -Text Documentation Guidelines.

#### **VI.1.3.3 Neoadjuvant Therapy – Treatment Effect**

- ✓ Added coding instruction:

- Document in Text-Pathology the treatment effect as stated in the path report, including the treatment response score.

## **VI.2 Surgery Introduction – First Course of Treatment**

- ✓ Added coding instruction:
  - Surgical procedures are coded in four-character alphanumeric codes, beginning with cases diagnosed January 1, 2023. For cases diagnosed prior to 2023, see Archived Volume I. Use case year of diagnosis to determine which Volume I to choose.

## **VI.2.3 Diagnostic or Staging Procedures**

- ✓ Updated Coding instruction, priority order note to:
  - **Note:** The CCR follows SEER guidelines for assigning surgery codes.  
**COG Facilities:** Please make note in your user defined data items when standards between CoC and CCR differ.

### **VI.2.3.1 Date of Diagnostic or Staging Surgical Procedures**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **VI.2.3.1.1 Diagnostic of Diagnostic or Staging Surgical Procedures Flag – *Deleted Page***

- ✓ Page deleted, all Date Flags are retired as of 2023.

## **VI.2.4 Surgery of Primary Site 2023 – *Renamed Page***

- ✓ Page renamed to Surgery of Primary Site 2023; from Surgery of Primary Site.
- ✓ Revised introduction to describe the 2023 surgery codes.
- ✓ Added coding instruction:
  - Record the site-specific coding scheme corresponding to the primary site or histology. See Appendix K.2 - STORE Surgery Codes for Site-Specific Surgery Codes.
- ✓ Updated multiple coding instructions to reference new 2023 surgery codes and updated two-digit codes to four-character alphanumeric coding.

### **VI.2.4.1 Date of Surgery**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **VI.2.4.1.1 Date of Surgery Flag – *Deleted Page***

- ✓ Page deleted, all Date Flags are retired as of 2023.

## **VI.2.5.1 Date of Sentinel Lymph Node Biopsy**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

### **VI.2.5.1.1 Date of Sentinel Lymph Node Flag – *Deleted Page***

- ✓ Page deleted, all Date Flags are retired as of 2023.

## **VI.2.6.1 Date of Regional Lymph Node Dissection**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **VI.2.6.1.1 Date of Regional Lymph Node Dissection Flag – Deleted Page**

- ✓ Page deleted, all Date Flags are retired as of 2023.

### **VI.3 Radiation Therapy - First Course of Treatment**

- ✓ Removed reference to Date Flag Guide. Date Flags are now retired as of 2023.
- ✓ Updated coding instruction to add sub-bullets regarding neoadjuvant therapy:
  - For each radiation phase, record in chronological order, the following information from the treatment summary:
    - Treatment start date.
    - If therapy is neoadjuvant per the treatment plan.
    - If treatment is started, but not completed, as prescribed.

### **VI.3.2 Date of Radiation Therapy**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **VI.3.2.1 Date of Radiation Therapy Flag – Deleted Page**

- ✓ Page deleted, all Date Flags are retired as of 2023.

### **VI.4 Chemotherapy - First Course of Treatment**

- ✓ Updated coding instruction to add sub-bullets regarding neoadjuvant therapy:
  - Record the following information in the appropriate text field (e.g. Chemotherapy agent recorded in Text-Chemotherapy).
    - Treatment start date.
    - If therapy is neoadjuvant per the treatment plan.
    - If treatment is started, but not completed, as prescribed.

### **VI.4.2 Date of Chemotherapy**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **VI.4.2.1 Date of Chemotherapy Flag – Deleted Page**

- ✓ Page deleted, all Date Flags are retired as of 2023.

### **VI.5 Hormone (Endocrine) Therapy - First Course of Treatment**

- ✓ Updated coding instruction to add sub-bullets regarding neoadjuvant therapy.
  - Record the following information in the appropriate text field (e.g. Hormone Therapy recorded in Text-Hormone Therapy).
    - Treatment start date.
    - If therapy is neoadjuvant per the treatment plan.
    - If treatment is started, but not completed, as prescribed.

### **VI.5.2. Date of Hormone Therapy**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **VI.5.2.1 Date of Hormone Therapy Flag – Deleted Page**

- ✓ Page deleted, all Date Flags are retired as of 2023.

#### **VI.6 Immunotherapy (Biological Response Modifier Therapy) - First Course of Treatment**

- ✓ Updated coding instruction to add sub-bullets regarding neoadjuvant therapy:
  - Record the following information in the appropriate text field (e.g. Immunotherapy agent recorded in Text-Immunotherapy).
    - Treatment start date.
    - If therapy is neoadjuvant per the treatment plan.
    - If treatment is started, but not completed, as prescribed.

#### **VI.6.2 Date of Immunotherapy Therapy**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **VI.6.2.1 Date of Immune Therapy Flag – Deleted Page**

- ✓ Page deleted, all Date Flags are retired as of 2023.

#### **VI.7.1 Date of Transplant/Endocrine Procedure**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **VI.7.1.1 Date of Transplant/Endocrine Procedure Flag – Deleted Page**

- ✓ Page deleted, all Date Flags are retired as of 2023.

#### **VI.8.1 Date of Other Therapy**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **VI.8.1.1 Date of Other Therapy Flag – Deleted Page**

- ✓ Page deleted, all Date Flags are retired as of 2023.

#### **VI.10 Protocol Participation**

- ✓ Added coding instructions:
  - Document in *Text – Remarks* the protocol study, clinical trial name or ID/number and study arm, as stated in the medical record.  
**Examples:**
    - Protocol: SWOG-SO777
    - Protocol: NSAPB B-39, RTOG 04313
    - Protocol: RTOG-00534
    - Protocol: CodeBreak 300: Colorectal Cancer/NCT05198934
    - For additional information regarding recording text, please see Appendix T -Text Documentation Guidelines.

- If a patient is on a treatment regimen that follows a protocol, but the patient is not actually enrolled in the study, then this data item does not apply. Assign code 00.

### **VII.2.1 Date of Last Contact (AKA-Date Last Patient Follow Up)**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **VII.2.1.1 Date of Last Contact Flag – *Deleted Page***

- ✓ Page deleted, all Date Flags are retired as of 2023.

### **VII.2.3 Date of Last Cancer (Tumor) Status**

- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **VII.2.3.1 Date of Last Cancer (Tumor) Status Flag – *Deleted Page***

- ✓ Page deleted, all Date Flags are retired as of 2023.

### **VII.2.9 Next Follow Up Facility – *Deleted Page***

- ✓ Page deleted, no longer in Volume II, Appendix B. Volume I was not updated to reflect this change until now, and this item will no longer be included in Volume I.

### **VII.2.9 Follow Up Physician**

- ✓ Page renumbered to VII.2.9 from VII.2.10 due to deletion of page VII.2.9 (above).

### **VII.2.10 Date of First Recurrence**

- ✓ Page renumbered to VII.2.10 from VII.2.11 due to deletion of page VII.2.9 (above).
- ✓ Updated reference to Date Format; from Date Format and Date Flag Guide. All Date Flags are retired as of 2023.

#### **VII.2.11.1 Date of First Recurrence Flag – *Deleted Page***

- ✓ Page deleted, all Date Flags are retired as of 2023.

### **VII.2.10.1 Type of First Recurrence**

- ✓ Page renumbered to VII.2.10.1 from VII.2.11.2 due to deletion of page VII.2.9 (above).

### **VII.2.11 Place of Death - Country**

- ✓ Page renumbered to VII.2.11 from VII.2.12 due to deletion of page VII.2.9 (above).

#### **VII.2.11.1 Place of Death - State**

- ✓ Page renumbered to VII.2.11.1 from VII.2.12.1 due to deletion of page VII.2.9 (above).

### **VIII.1 Text Remarks**

- ✓ Added coding instructions for protocol participation:
  - If the patient is participating in a protocol study, document the protocol study, clinical trial name or ID/number and study arm, as stated in the medical record. See Protocol Participation.

### Examples:

- Protocol: SWOG-SO777
- Protocol: NSAPB B-39, RTOG 04313
- Protocol: RTOG-00534
- Protocol: CodeBreak 300: Colorectal Cancer/NCT05198934

### IX.1.2 Modified Record

- ✓ Updated page to include revisions supported by Volume II. There are multiple updates to the page so, we suggest re-reading the page for the updates.

## **CHANGES TO APPENDICES**

### Appendix G - Codes for Casefinding

- ✓ Updated effective date to:
  - Effective for Cases diagnosed between October 1, 2022 and September 30, 2023.
- ✓ No new reportable codes for the 2023 list.
- ✓ No changes to the reportable list. Although some of the D codes (for benign neoplasms that became malignant neoplasms) were moved to the supplemental list.
- ✓ Codes on the supplemental list were removed because they were felt as not meaningful.

### Appendix K.1 - STORE-Surgery Codes 2010-2022 – *Renamed Page*

- ✓ Renamed to Appendix K.1 to STORE Surgery Codes for 2010-2022; from K. STORE Surgery Codes.
- ✓ Added K.1 to all pages as a reminder that the user is in the surgery codes for cases diagnosed January 1, 2010 through December 31, 2022.
- ✓ Update introduction to include link to Appendix K.2 Store Surgery Codes for 2023+.
- ✓ Updated header on each page to:
  - For cases diagnosed between January 1, 2010 through December 31, 2022.

### K.2 New STORE-Surgery Codes for 2023+ – *New Page*

- ✓ Created new Appendix K.2 to introduce and specify new alpha-numeric surgery codes for cases diagnosed January 1, 2023 and forward.
- ✓ Added introduction to include links for historical surgery code references.
- ✓ Added guideline to indicate the use of these codes are for cases 01/01/2023 and forward.
- ✓ Added header on each page to:
  - For cases diagnosed on or after January 1, 2023.
- ✓ Added new four-character alpha-numeric surgery Codes for 2023+ to all sites.
  - B-Codes for skin site.
  - A-Codes for remaining sites.

### Appendix M- Q-Tips

- ✓ Added list of 2022 Q-Tips published to FLccSC:
- ✓ Q-Tip Series- Primary Brain Cancer Coding Clarifications – Surgery, SSDIs, Grade
  - Brain Surgery of Primary Site Coding Clarifications
  - Brain SSDIs
  - Brain Tumor Clinical and Pathological Grade



## Appendix Q Site- Specific Data Items (SSDIs)

- ✓ SSDIs are organized alphabetically by section, removed AJCC Chapter. AJCC Chapter is no longer referenced in the SSDI Manual.
  - ✓ Removed AJCC Chapter from every schema.
  - ✓ New Schemas IDs for 2023+ (Required by CCR), and added an end date for collection of old Schema IDs:
    - Anus
      - Schema ID: 00210 (2018-2022)  
09210 (2023+) – Added existing P16, dx 2023+.
    - Appendix
      - Schema ID: 00190 (2018-2022)  
09190 (2023+) – Added new Histologic Subtype SSDI, dx 2023+.
    - Melanoma Skin
      - Schema ID: 00470 – Added new Clinical Margin Width SSID, dx 2023+.
    - Medulloblastoma – New Schema for 2023+.
      - Schema ID: 9724
- Note: The schemas below were updated due to moving Medulloblastoma into its own schema.**
- Brain
    - Schema ID: 00721 (2018-2022)  
09721 (2023+)
  - CNS Other
    - Schema ID: 00722 (2018-2022)  
09722 (2023+)
  - Intracranial Gland
    - Schema ID: 00723 (2018-2022)  
09723 (2023+) – Includes existing Brain Molecular Markers, dx 2023+.
- ✓ No longer collected with date of diagnosis after January 1,2023:
  - Estrogen Receptor Total Allred Score (2018-2022)
  - Progesterone Receptor Total Allred Score (2018-2022)
- ✓ SSDI Retired in 2023 – LN Status Femoral-Inguinal, Para-aortic, Pelvic. This data item was converted to three new data items in 2022, for cases diagnosed 2018 and forward.
  - LN Status Femoral-Inguinal
  - LN Status Para-Aortic
  - LN status Pelvic
- ✓ Additional Stage-related Data Items section
  - Updated introduction with v2023 information.
  - Added new Table 4, for SSDIs Implemented in 2023.
  - Revised Table 5, removed schema name column and added/removed items collected/no longer collected (noted above).

## Appendix R – Coding Resources

- ✓ Added new manuals and updated publication date of revised manuals.

## Appendix S- Historical Coding and Staging Manual Requirements for CCR

- ✓ Added manuals that became historical in 2023 to the standard setter lists.

## Appendix T - Text Documentation Guidelines

- ✓ Removed COVID-19 note since collection of COVID-19 is no longer required for cases diagnosed 2023+:
  - **Note:** Text documentation guidelines for COVID-19 information are not included in this appendix and can be found on the SEER Website under COVID-19-Abstraction Guidance.
- ✓ Text – Remarks – Added guidelines and examples:
  - If the patient is participating in a protocol study, document the protocol study, clinical trial name or ID/number and study arm, as stated in the medical record.
    - Examples:**
      - Protocol: SWOG-SO777
      - Protocol: NSAPB B-39, RTOG 04313
      - Protocol: RTOG-00534
      - Protocol: CodeBreak 300: Colorectal Cancer/NCT05198934
- ✓ Text – Physical Examination – Added and revised existing guidelines and examples:
  - Record the Managing/Treating physician’s impression/statement of the patient’s overall *clinical* response to neoadjuvant therapy.
    - Record required patient demographics if not recorded in Text – Remarks.
      - Examples:**
        - Analytic Case*
          - 10/2/21 pt presented for US guided lt breast core bx due to susp findings on screening mammo. Palp mass noted in UOQ lt breast w/o palp ax LAD noted on exam.
          - 9/24/21 cc: rectal cancer dx at XYZ Hosp, s/p neoadjuvant chemo, XRT w/partial response, per MD; presents for surgical resection; PE: wnl.
- ✓ Text – X-Ray/Scans – Revised the following guidelines and added example #4:
  - Diagnostic statement/impression of the radiologist or endoscopist, including response to neoadjuvant therapy.
    - Example #4
      - 09/28/21 MRI Pelvis: Interval DECR in high rectal tumor, now 2.8CM, PREV seen LNs resolved.
- ✓ Text – Scopes – Added the following guidelines:
  - Treatment effect to neoadjuvant therapy as stated in the pathology report, including the treatment response score.
  - Pertinent biomarker results (recorded in SSDIs, used for staging, evaluate response to neoadjuvant therapy, etc.).
    - Example #3
      - 11/11/21 Rectum: 1.5CM Adenocarcinoma, G2 invading through muscularis propria into pericorectal tissue; Margins(-) CRM by 13MM, TX effect: Present: Residual cancer w/evident tumor regression, (partial response, score 2), LVI(-), Perineural INV(+), Tumor Deposits: 0, 0+/24 mesorectal LNs, ypT3 N0.
- ✓ Text – Pathology Findings – Added the following guidelines and added example #3:
  - Diagnostic statement/impression and/or stage of the endoscopist, including response to neoadjuvant therapy.
- ✓ Text – Radiation Therapy – Revised /added guidelines below and added example #3, based on Volume I Errata-22<sup>nd</sup> Edition:
  - Replaced existing bullet text:
  - Record information for **all** radiation therapy phases in the first Text – Radiation Therapy field.
    - Your software vendor may allow text to be entered for *each* phase, but only one text field for all phases will be transmitted to the CCR and used during Visual Editing

and other QC processes to validate coded values are correct. Documenting all the information in Phase I text eliminates the possibility of some text being “lost” when the case is transmitted to CCR.

- For each radiation phase, record in chronological order, the following information from the treatment summary:
  - Treatment start date.
  - If therapy is neoadjuvant per the treatment plan.
  - If treatment is started, but not completed, as prescribed.

Example #3

10/27/21-11/02/21 Neo-adj Whole pelvis 2500cGy 6MV photons 5FX, Dose/FX: 500cGy Planning Technique: 3D Conformal.

- ✓ Systemic Therapy Text Fields – Added the following guidelines and example:

- Record the following information in the appropriate text field (e.g. Chemotherapy agent recorded in Text-Chemotherapy).
  - Treatment start date.
  - If therapy is neoadjuvant per the treatment plan.
  - If treatment is started, but not completed, as prescribed.

Example:

- Neoadjuvant chemo:
  - Text - Chemotherapy: 05/05/21-09/03/21 Neo-adj FOLFOX (fluorouracil, oxaliplatin) x 8 cycles.